Tags

Type your tag names separated by a space and hit enter

Infection prevention in bone marrow transplantation and radiation patients.
NCI Monogr 1990; (9):73-85NM

Abstract

This article reviews the prevention of oral and systemic infection in bone marrow transplantation and radiation patients. Prophylaxis of herpes virus reactivation in bone marrow transplant and leukemic patients has resulted in reduced morbidity associated with their medical management. In order to reduce the risk of systemic infection, reduction in ulcerative mucositis is desirable. The use of antifungal and antibacterial agents has not been encouraging to date. Cytoprotective agents have shown some initial success in preventing mucosal breakdown. Further study is required to confirm these initial results.

Authors+Show Affiliations

Cancer Control Agency of British Columbia, Vancouver, Canada.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2111470

Citation

Epstein, J B.. "Infection Prevention in Bone Marrow Transplantation and Radiation Patients." NCI Monographs : a Publication of the National Cancer Institute, 1990, pp. 73-85.
Epstein JB. Infection prevention in bone marrow transplantation and radiation patients. NCI Monogr. 1990.
Epstein, J. B. (1990). Infection prevention in bone marrow transplantation and radiation patients. NCI Monographs : a Publication of the National Cancer Institute, (9), pp. 73-85.
Epstein JB. Infection Prevention in Bone Marrow Transplantation and Radiation Patients. NCI Monogr. 1990;(9)73-85. PubMed PMID: 2111470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Infection prevention in bone marrow transplantation and radiation patients. A1 - Epstein,J B, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 73 EP - 85 JF - NCI monographs : a publication of the National Cancer Institute JO - NCI Monogr IS - 9 N2 - This article reviews the prevention of oral and systemic infection in bone marrow transplantation and radiation patients. Prophylaxis of herpes virus reactivation in bone marrow transplant and leukemic patients has resulted in reduced morbidity associated with their medical management. In order to reduce the risk of systemic infection, reduction in ulcerative mucositis is desirable. The use of antifungal and antibacterial agents has not been encouraging to date. Cytoprotective agents have shown some initial success in preventing mucosal breakdown. Further study is required to confirm these initial results. SN - 0893-2751 UR - https://www.unboundmedicine.com/medline/citation/2111470/Infection_prevention_in_bone_marrow_transplantation_and_radiation_patients_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -